Sorry, your browser is out of date. To view this page correctly, please install a modern browser (Microsoft Edge, Firefox or Google Chrome).
SAI - Detailed view
Please log in as a company employee using your SIMIS-Login. For further information please see the FAQ.
Livmarli 9.5 mg/ml, Lösung zum Einnehmen 30
Drug
Livmarli, Lösung zum Einnehmen
Behandlung von cholestatischem Pruritus bei Patienten mit Alagille-Syndrom (ALGS)
04.99.0. – various
HAM – Human medicine
LSOR – Oral solution
S – synthetic products for human use
B – Dispensed on prescription by a physician or veterinarian (B)
Z – approved
7/18/2024
7/17/2029
Dosage strength
Livmarli 9.5 mg/ml, Lösung zum Einnehmen
Behandlung von cholestatischem Pruritus bei Patienten mit Alagille-Syndrom (ALGS)
01
Z – approved
Package
No information made available
A/NR – Authorised / not referenced
30 ml
001
Z – approved
Declaration
Component Solution
9.5 mg maralixibatum
maralixibati chloridum
maralixibati chloridum
propylenglycolum
aqua purificata
dinatrii edetas
0.124 mg natrium
sucralosum
aromatica
propylenglycolum
364.55 mg propylenglycolum
aqua purificata
dinatrii edetas
0.124 mg natrium
sucralosum
aromatica
propylenglycolum
364.55 mg propylenglycolum
Authorisation holder
Mirum Pharmaceuticals AG
Baarerstrasse 22
6300 Zug (ZG)
Baarerstrasse 22
6300 Zug (ZG)
Date of revision of the text
8/1/2024
Please log in as a company employee using your SIMIS-Login. For further information please see the FAQ.
Data source: Swissmedic, *authorisation holder, **Refdata foundation, ***FOPH.